Phase II Study of the combination of Elotuzumab with Lenalidomide as Maintenance Therapy post Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Trial Profile

Phase II Study of the combination of Elotuzumab with Lenalidomide as Maintenance Therapy post Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs Elotuzumab (Primary) ; Lenalidomide (Primary) ; Dexamethasone; Diphenhydramine; Famotidine
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Mar 2018 Planned End Date changed from 1 Apr 2019 to 1 Apr 2021.
    • 12 Mar 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
    • 12 Dec 2017 Preliminary results (n=55) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top